Jaguar Health, Inc. (NASDAQ:JAGX) Short Interest Update

Jaguar Health, Inc. (NASDAQ:JAGX) was the target of a large drop in short interest in June. As of June 30th, there was short interest totalling 313,000 shares, a drop of 11.4% from the June 15th total of 353,400 shares. Currently, 7.5% of the shares of the stock are sold short. Based on an average daily volume of 1,060,000 shares, the days-to-cover ratio is currently 0.3 days.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded shares of Jaguar Health from a “sell” rating to a “hold” rating in a research report on Wednesday, July 10th.

Jaguar Health Trading Down 1.9 %

NASDAQ:JAGX traded down $0.08 during mid-day trading on Wednesday, reaching $4.09. 370,758 shares of the company were exchanged, compared to its average volume of 831,091. Jaguar Health has a 12 month low of $3.07 and a 12 month high of $41.76. The company has a fifty day moving average of $6.29 and a 200 day moving average of $6.62. The company has a quick ratio of 1.39, a current ratio of 1.89 and a debt-to-equity ratio of 1.84.

Jaguar Health (NASDAQ:JAGX) last issued its quarterly earnings data on Tuesday, May 14th. The biotechnology company reported ($3.60) EPS for the quarter. Jaguar Health had a negative return on equity of 642.15% and a negative net margin of 377.95%. The company had revenue of $2.35 million for the quarter. As a group, equities analysts predict that Jaguar Health will post -5.42 EPS for the current fiscal year.

About Jaguar Health

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.